Export file:


  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text


  • Citation Only
  • Citation and Abstract

Identification of biomarkers associated with Parkinson’s disease by gene expression profiling studies and bioinformatics analysis

Bioinformatics and Human Electrophysiology Laboratory, Department of Informatics, Ionian University, Greece

Special Issues: Novel modeling methodologies for the neuropathological dimensions of Parkinson’s disease

Parkinson’s disease (PD) is associated with a selective loss of the neurons in the midbrain area called the substantia nigra pars compacta and the loss of projecting nerve fibers in the striatum. Predominant pathological hallmarks of PD are the degeneration of discrete neuronal populations and progressive accumulation of α-synuclein–containing intracytoplasmic inclusions called Lewy bodies and dystrophic Lewy neuritis. There is currently no therapy to terminate or delay the neurodegenerative process as the exact mechanisms underlying the pathogenesis of PD require further investigation. The identification and validation of novel biomarkers for the diagnosis of PD is a great challenge using contemporary approaches and optimizing sampling handling as well as interpretation using bioinformatics analysis. In this review, recent evidences associated with multi-omic data-sets and molecular mechanisms underlying PD are examined. A combined mapping of several transcriptional evidences could establish a patient-specific signature for early diagnose of PD though eligible systems biology tools, which can also help develop effective drug-based therapeutic approaches.
  Article Metrics


1. Obeso J, Rodriguez-Oroz M, Goetz C, et al. (2010) Missing pieces in the Parkinson's disease puzzle. Nat Med 16: 653–661.    

2. Musgrove R, Helwig M, Bae E, et al. (2019) Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. J Clin Invest 130: 3738–3753.

3. Lill C (2016) Genetics of Parkinson's disease. Mol Cell Probes 30: 386–396.    

4. Reale M, Iarlori C, Thomas A, et al. (2009) Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 23: 55–63.    

5. Dias V, Junn E, Mouradian M (2013) The role of oxidative stress in Parkinson's disease. J Parkinsons Dis 3: 461–491.    

6. Taylor J, Main B, Crack P (2013) Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease. Neurochem Int 62: 803–819.    

7. Kalia L, Lang A (2015) Parkinson's disease. Lancet 386 :896–912.

8. Valdes P, Schneider B (2016) Gene therapy: A promising approach for neuroprotection in Parkinson's disease? Front Neuroanat 10: 123.

9. Ferrer I, Lopez-Gonzalez I, Carmona M, et al. (2012) Neurochemistry and the non-motor aspects of PD. Neurobiol Dis 46: 508–526.    

10. Scherzer C, Grass J, Liao Z, et al. (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene α-synuclein. Proc Natl Acad Sci USA 105: 10907–10912.    

11. Miller D, O'Callaghan J (2015) Biomarkers of Parkinson's disease: Present and future. Metabolism 64: S40–S46.    

12. Harraz M, Dawson T, Dawson V (2011) MicroRNAs in Parkinson's disease. J Chem Neuroanat 42: 127–130.    

13. Gasser T (2009) Genomic and proteomic biomarkers for Parkinson disease. Neurology 72: 27–31.

14. Haque M, Thomas K, D'Souza C, et al. (2008) Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc Natl Acad Sci USA 105: 1716–1721.    

15. Valente E, Bentivoglio A, Dixon P, et al. (2001) Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35–p36. Am J Hum Genet 68: 895–900.    

16. Kitada T, Asakawa S, Hattori N, et al. (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605–608.    

17. McKeith I (2004) Dementia with Lewy bodies. Dialogues Clin Neurosci 3: 333–341.

18. Farrer M (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7: 306–318.

19. Funayama M, Hasegawa K, Kowa H, et al. (2002) A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1. Ann Neurol 51: 296–301.    

20. Mencacci N, Isaias I, Reich M, et al. (2014) Parkinson's disease in GTP cyclohydrolase 1 mutation carriers. Brain 137: 2480–2492.    

21. Olgiati S, Quadri M, Fang M, et al. (2016) DNAJC6 mutations associated with early-onset Parkinson's disease. Ann Neurol 79: 244–256.    

22. Jiang F, Wu Q, Sun S, et al. (2019) Identification of potential diagnostic biomarkers for Parkinson's disease. FEBS Open Bio 9: 1460–1468.    

23. Wang Q, Zhang Y, Wang M, et al. (2019) The landscape of multiscale transcriptomic networks and key regulators in Parkinson's disease. Nat Commun 10: 5234.    

24. Chi J, Xie Q, Jia J, et al. (2018) Integrated analysis and identification of novel biomarkers in Parkinson's disease. Front Aging Neurosci 10: 178.    

25. Kong P, Lei P, Zhang S, et al. (2018) Integrated microarray analysis provided a new insight of the pathogenesis of Parkinson's disease. Neurosci Lett 662: 51–58.    

26. Wang C, Chen L, Yang Y, et al. (2019) Identification of potential blood biomarkers for Parkinson's disease by gene expression and DNA methylation data integration analysis. Clin Epigenetics 11: 24.    

27. George G, Singh S, Lokappa S, et al. (2019). Gene co-expression network analysis for identifying genetic markers in Parkinson's disease-a three-way comparative approach. Genomics 111: 819–830.    

28. Kim J, Inoue K, Ishii J, et al. (2007) A MicroRNA feedback circuit in midbrain dopamine neurons. Science 317: 1220–1224.    

29. Wang G, van der Walt J, Mayhew G, et al. (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82: 283–289.    

30. Mouradian M (2012) MicroRNAs in Parkinson's disease. Neurobiol Dis 46: 279–284.    

31. Junn E, Lee K, Jeong B, et al. (2009) Mouradian Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc Natl Acad Sci USA 106: 13052–13057.    

32. Doxakis E (2010) Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. Biol Chem 285: 12726–12734.    

33. van der Walt J, Noureddine M, Kittappa R, et al. (2004) Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am J Hum Genet 74: 1121–1127.    

34. Schulz J, Takousis P, Wohlers I, et al. (2019) Meta‐analyses identify differentially expressed microRNAs in Parkinson's disease. Ann Neurol 85: 835–851.    

35. Uwatoko H, Hama Y, Iwata I, et al. (2019) Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease. Mol Brain 12: 49.    

36. Chen L, Yang J, Lü J, et al. (2018) Identification of aberrant circulating miRNAs in Parkinson's disease plasma samples. Brain Behav 8: e00941.    

37. Goh S, Chao Y, Dheen S, et al. (2019) Role of MicroRNAs in Parkinson's Disease. Int J Mol Sci 20: pii: E5649.

38. Peeraully T, Tan E (2012) Genetic variants in sporadic Parkinson's disease: East vs West. Parkinsonism Relat Disord 18: S63–S65.

39. Chikina M, Gerald C, Li X, et al. (2015) Low-variance RNAs identify Parkinson's disease molecular signature in blood. Mov Disord 30: 813–821.    

40. Qian Y, Yang X, Xu S, et al. (2018) Detection of microbial 16S rRNA gene in the blood of patients with Parkinson's disease. Front Aging Neurosci 10: 156.    

41. Li Y, Wong G, Humphrey J, et al. (2019) Prioritizing Parkinson's disease genes using population-scale transcriptomic data. Nat Commun 10: 994.    

42. Chang D, Nalls M, Hallgrímsdóttir I, et al. (2017) A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet 49: 1511–1516.    

43. Garnier S, Truong V, Brocheton J, et al. (2013) Genome-wide haplotype analysis of cis expression quantitative trait loci in monocytes. PLoS Genet 9: e1003240.    

44. Sekiyama K, Takamatsu Y, Waragai M, et al. (2014) Role of genomics in translational research for Parkinson's disease. Biochem Biophys Res Commun 452: 226–235.    

45. Servant N, Roméjon J, Gestraud P, et al. (2014) Bioinformatics for precision medicine in oncology: principles and application to the SHIVA clinical trial. Front Genet 5: 152.

46. Dong N, Zhang X, Liu Q (2017) Identification of therapeutic targets for Parkinson's disease via bioinformatics analysis. Mol Med Rep 15: 731–735.    

47. Al-Ouran R, Wan Y, Mangleburg C, et al. (2019) A portal to visualize transcriptome profiles in mouse models of neurological disorders. Genes (Basel)10: pii: E759.

48. Fu L, Fu K (2015) Analysis of Parkinson's disease pathophysiology using an integrated genomics-bioinformatics approach. Pathophysiology 22: 15–29.    

49. Mariani E, Frabetti F, Tarozzi A, et al. (2016) Meta-Analysis of Parkinson's Disease transcriptome data using TRAM software: Whole substantia nigra tissue and single dopamine neuron differential gene expression. PLoS One 11: e0161567.    

50. Glaab E (2018) Computational systems biology approaches for Parkinson's disease. Cell Tissue Res 373: 91–109.    

51. Lottaz C, Toedling J, Spang R (2007) Annotation-based distance measures for patient subgroup discovery in clinical microarray studies. Bioinformatics 23: 2256–2264.    

52. Hu Y, Pan Z, Hu Y, et al. (2017) Network and pathway-based analyses of genes associated with Parkinson's disease. Mol Neurobiol 54: 4452–4465.    

53. Cheng HC, Ulane C, Burke R (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 67: 715–725.    

54. Palfi S, Gurruchaga J, Ralph G, et al. (2014) Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: A dose escalation, open-label, phase 1/2 trial. Lancet 383: 1138–1146.    

55. Diao H, Li X, Hu S, et al. (2012) Gene expression profiling combined with bioinformatics analysis identify biomarkers for Parkinson disease. PLoS One 7: e52319.    

56. Xu C, Chen J, Xu X, et al. (2018) Potential therapeutic drugs for Parkinson's disease based on data mining and bioinformatics analysis. Parkinsons Dis 2018: 3464578.

57. Airavaara M, Voutilainen MH, Wang Y, et al. (2012) Neurorestoration. Parkinsonism Relat Disord 18: S143–146.

58. Francardo V, Schmitz Y, Sulzer D, et al. (2017) Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease. Exp Neurol 298: 137–147.    

59. Nayak L, Henchcliffe C (2008) Rasagiline in treatment of Parkinson's disease. Neuropsychiatr Dis Treat 4: 23–32.

60. Marsili L, Marconi R, Colosimo C (2017) Treatment strategies in early Parkinson's disease. Int Rev Neurobiol 132: 345–360.    

61. Magyar K, Stocchi F, Fossati C, et al. (2015) Rasagiline for the treatment of Parkinson's disease: an update. Expert Opin Pharmacother 16: 2231–2241.    

62. McCormack P (2014) Rasagiline: A review of its use in the treatment of idiopathic Parkinson's disease. CNS Drugs 28: 1083–1097.    

63. Alborghetti M, Nicoletti F (2019) Different generations of Type-B monoamine oxidase inhibitors in Parkinson's disease: From bench to bedside. Curr Neuropharmacol 17: 861–873.    

64. Bette S, Shpiner D, Singer C, et al. (2018) Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: A review of the current clinical evidence. Ther Clin Risk Manag 14: 1737–1745.    

65. Leegwater-Kim J, Waters C (2006) Tolcapone in the management of Parkinson's disease. Expert Opin Pharmacother 7: 2263–2270.    

66. Jiang D, Wang H, Wang Y, et al. (2019) Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: A systematic review. Neurol Sci, 1–9.

67. Avila A, Caballol N, Martín-Baranera M, et al. (2019) Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease. Acta Neurol Scand 140: 23–31.    

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Article outline

Show full outline
Copyright © AIMS Press All Rights Reserved